Aroa Biosurgery (ARX) is a NZ-listed Healthcare company in Medical - Devices with a market capitalization of A
95M, trading at A$0.56 on the ASX. This SniperIQ fundamentals page covers Aroa Biosurgery's valuation (P/E 31.0x, P/B 2.4x), profitability (net margin 4.6%), revenue (A$92M in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Market CapA
95M
P/E (TTM)31.0x
Net Margin4.6%
Revenue (FY26)A$92M
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Aroa Biosurgery's market cap?
Aroa Biosurgery (ARX) has a market capitalization of approximately A
95M, trading at A$0.56 on the ASX. Market cap moves with the live share price.
What is Aroa Biosurgery's P/E ratio?
Aroa Biosurgery's trailing twelve-month P/E ratio is 31.0x, with a price-to-book (P/B) of 2.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Aroa Biosurgery?
Aroa Biosurgery runs a net profit margin of 4.6%, a gross margin of 86.0%, and an operating margin of 5.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Aroa Biosurgery generate?
Aroa Biosurgery reported revenue of A$92M for fiscal year 2026, with net income of A$4M and earnings per share (EPS) of 0.012. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Aroa Biosurgery pay a dividend?
Aroa Biosurgery does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Aroa Biosurgery financially healthy?
Aroa Biosurgery carries a debt-to-equity ratio of 0.06x and a current ratio of 4.77x, with a market beta of 0.85. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Aroa Biosurgery a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Aroa Biosurgery (ARX) the key facts are: market cap A
95M, P/E 31.0x, revenue A$92M, 52-week range 0.495-0.8. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Aroa Biosurgery's full fundamentals live
Get Aroa Biosurgery's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.